Israel - hebreiska - Ministry of Health

promedico ltd - sodium ioxitalamate - תמיסה להזרקה - sodium ioxitalamate 21 g / 100 ml - ioxitalamic acid - ioxitalamic acid - contrast medium for retrograd cystography.

Israel - hebreiska - Ministry of Health

romat ltd - cyanocobalamin 1 mg/ml; thiamine (vit b1) hydrochloride 100 mg/ml - solution for injection - vitamin b1, 12 supplement in cattle, horses, swine, sheep, dogs and cats.

Israel - hebreiska - Ministry of Health

מדוגר מכשור רפואי בע"מ - רופא - ans dbs systems are indicated for use in unilateral or bilateral stimulation of the thalamus, including the internal globus pallidus(gpi) or subthalamic nucleus (stn) in patients with levadopa-responsive parkinson's disease

Israel - hebreiska - Ministry of Health

אלקליל בעמ - דאודורנט

Israel - hebreiska - Ministry of Health

אלקליל בעמ - דאודורנט

Israel - hebreiska - Ministry of Health

אלקליל בעמ - רחצת הגוף

Israel - hebreiska - Ministry of Health

zvi lifshitz optic - רופא - מכשירים לרפואת עיניים

Israel - hebreiska - Ministry of Health

promedico ltd - meglumine ioxitalamate; sodium ioxitalamate - תמיסה להזרקה - sodium ioxitalamate 9.66 %; meglumine ioxitalamate 65.09 % - ioxitalamic acid

Israel - hebreiska - Ministry of Health

אינטרביוטי קוסמטיקס ישראל בעמ - דאודורנט

Israel - hebreiska - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob